Recruiting

A Research Study Comparing How Well Different Doses of the Medicine NNC0662-0419 Lower Blood Sugar in People With Type 2 Diabetes

This study is being done to look at the effect and safety of different doses of NNC0662-0419 in people living with type 2 diabetes when compared to placebo or semaglutide. The purpose of this clinical study is to find out if NNC0662-0419 is effective and safe for treating people living with type 2 diabetes. Participants will get either NNC0662-0419, semaglutide or placebo. Which treatment participants get is decided by chance. NNC0662-0419 is a new medicine which cannot be prescribed by doctors but has previously…

ClinicalTrials.gov IDNCT07415954

PhasePHASE2

Enrollment270

SponsorNovo Nordisk A/S

Age18 Years

SexALL

I'm interested View official listing

Conditions studied

Diabetes Mellitus, Type 2

About this study

Interventions

Drug: NNC0662-0419 — NNC0662-0419 will be administered subcutaneously.
Drug: Semaglutide — Semaglutide will be administered subcutaneously.
Drug: Placebo — Placebo will be administered subcutaneously.

Primary outcomes

Change in glycated haemoglobin (HbA1c) (week 16) (From baseline (week 0) to week 16)
Change in HbA1c (week 28) (From baseline (week 0) to week 28)
Change in HbA1c (week 40) (From baseline (week 0) to week 40)

Eligibility information

Inclusion criteria * Male or female (sex at birth). * Age 18-75 years (both inclusive) at the time of signing the informed consent. * Glycated haemoglobin (HbA1c) of 7.0-10.0 percent (%) (53-86 millimoles per mole \[mmol/mol\]) (both inclusive) as assessed by central laboratory at screening. * Willingness to obtain a high weight loss (greater than \[\>\] 25% of weight at baseline). Exclusion criteria * Treatment with any medication for the indication of diabetes or obesity other than stated in the inclusion criteria within 90 days before screening. However, short term insulin treatment for a maximum of 14 consecutive days and prior insulin treatment for gestational diabetes are allowed. * Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination. * Known hypoglycaemic unawareness as indicated by the investigator according to Clarke's Questionnaire.

Study locations

First Valley Medical Group, Lancaster, California 93534 United States
Torrance Clinical Research Institute, Inc., Lomita, California 90717 United States
Ark Clinical Research, Long Beach, California 90815 United States
Pacific Clinical Studies, Los Alamitos, California 90720 United States
Wetlin Research Associates, Inc., San Diego, California 92120 United States
Diablo Clinical Research, Inc., Walnut Creek, California 94598 United States
Encore Medical Research LLC, Hollywood, Florida 33024 United States
Bioclinical Research Alliance, Miami, Florida 33155 United States
South Broward Research LLC, Miramar, Florida 33027 United States
West Orange Endocrinology, Ocoee, Florida 34761 United States

Showing 10 of 63 reported sites. See the official listing for all locations.

Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.

Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-27.